EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access

Circulating tumour DNA analysis for early detection of lung cancer: a systematic review

W K Jacky Lam iD, Jinyue Bai, Mary-Jane L Ma iD, Y T Tommy Cheung, Peiyong Jiang

Annals of Translational Medicine · 2024-08 · 12 (4) · 64-64

DOI: 10.21037/atm-23-1572 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Translational Medicine, 2024-08. Verfasst von W K Jacky Lam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating tumor DNA (ctDNA) analysis has been applied in cancer diagnostics including lung cancer. Specifically for the early detection purpose, various modalities of ctDNA analysis have demonstrated their potentials. Such analyses have showed diverse performance across different studies.

Methods

We performed a systematic review of original studies published before 1 January 2023. Studies that evaluated ctDNA alone and in combination with other biomarkers for early detection of lung cancer were included.

Results

The systematic review analysis included 56 original studies that were aimed for early detection of lung cancer. There were 39 studies for lung cancer only and 17 for pan-cancer early detection. Cancer and control cases included were heterogenous across studies. Different molecular features of ctDNA have been evaluated, including 7 studies on cell-free DNA concentration, 17 on mutation, 29 on methylation, 5 on hydroxymethylation and 8 on fragmentation patterns. Among these 56 studies, 17 have utilised different combinations of the above-mentioned ctDNA features and/or circulation protein markers. For all the modalities, lower sensitivities were reported for the detection of early-stage cancer.

Conclusions

The systematic review suggested the clinical utility of ctDNA analysis for early detection of lung cancer, alone or in combination with other biomarkers. Future validation with standardised testing protocols would help integration into clinical care.

Schlagwörter

Stichwörter der Autor:innen

Liquid biopsycirculating tumor DNA (ctDNA)lung cancermulti-cancer early detection

Autor:innen und Institutionen

  • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China.
  • Centre for Novostics, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, China.
  • Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.
  • State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.
  • Department of Pathology, Princess Margaret Hospital, Kwai Chung, Hong Kong, China.

ORCID-Profile: W K Jacky Lam, Mary-Jane L Ma

Zitieren

APA

Lam, W. K. J., Bai, J., Ma, M. L., Cheung, Y. T. T., & Jiang, P. (2024). Circulating tumour DNA analysis for early detection of lung cancer: a systematic review. Annals of Translational Medicine, 12(4), 64-64. https://doi.org/10.21037/atm-23-1572

Vancouver

Lam WKJ, Bai J, Ma ML, Cheung YTT, Jiang P. Circulating tumour DNA analysis for early detection of lung cancer: a systematic review. Annals of Translational Medicine. 2024;12(4):64-64. doi:10.21037/atm-23-1572

BibTeX
@article{Lam2024,
  author = {Lam, W K Jacky and Bai, Jinyue and Ma, Mary-Jane L and Cheung, Y T Tommy and Jiang, Peiyong},
  title = {Circulating tumour DNA analysis for early detection of lung cancer: a systematic review},
  journal = {Annals of Translational Medicine},
  year = {2024},
  volume = {12},
  number = {4},
  pages = {64--64},
  doi = {10.21037/atm-23-1572}
}
Kostenlos starten →